A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03970447 |
|
Recruitment Status :
Recruiting
First Posted : May 31, 2019
Last Update Posted : May 16, 2024
|
Sponsor:
Global Coalition for Adaptive Research
Collaborators:
Bayer
Kazia Therapeutics Limited
Kintara Therapeutics, Inc.
Biohaven Pharmaceuticals, Inc.
Vigeo Therapeutics, Inc.
Polaris Group
Information provided by (Responsible Party):
Global Coalition for Adaptive Research
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | June 2026 |
| Estimated Study Completion Date : | June 2028 |